Xencor, Inc. announced yesterday that the Company received a milestone payment under a technology license agreement with Boehringer Ingelheim. The amount of the milestone payment and the oncology drug target have not been disclosed.
The payment was triggered by a regulatory submission to begin Phase 1 clinical trials of a novel monoclonal antibody that was optimized using Xencor’s XmAb® antibody engineering technology. This is the second XmAb candidate entering human clinical trials under the agreement with Boehringer Ingelheim.
The two companies entered a license agreement in 2007 to use Xencor’s proprietary XmAb antibody-dependent cell cytotoxicity (ADCC) technology to enhance the potency of therapeutic antibodies. XmAb engineered high ADCC Fc domains give antibodies more tumor killing power by improving their capacity to recruit the immune system to target cancer cells.
The companies have also announced a collaboration agreement in February this year, for certain Xencor biosuperior monoclonal antibodies.
“The clinical pipeline of antibodies with Xencor’s Fc engineering technology continues to grow, and we now have six programs being developed in the clinic either by partners or on our own that employ our technology,” said Bassil Dahiyat, Ph.D., CEO of Xencor.
“Our XmAb technology provides key differentiating features such as heightened potency and convenient dosing for both novel antibodies and biosuperiors,” Dahiyat added.
Source: Xencor press release